NACinCOVID2: NAC for Attenuation of COVID-19 Symptomatology
Study Details
Study Description
Brief Summary
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 2 |
Detailed Description
STUDY DESIGN: Randomized double-blinded placebo-controlled trial
ELIGIBILITY
Inclusion criteria:
-
age 18 years and older
-
participants will need daily access to use of a smartphone for at least six weeks from time of enrollment
-
Positive COVID-19 test within 10 days of date of enrollment
-
not already hospitalized for treatment of COVID
Exclusion criteria:
-
pregnant
-
already hospitalized for treatment of COVID
PROTOCOL
-
50:50 randomization: half of participants will take NAC, half will take placebo
-
Participants will take NAC/placebo following this outpatient protocol:
-
2400 mg x 1 PO then
-
1200 mg PO BID x 14 days
-
Participants will complete an online symptom-tracker for six weeks (daily for three weeks, weekly for three weeks)
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: NAC Group receiving intervention/study drug NAC |
Drug: N-acetylcysteine
N-acetylcysteine
Other Names:
|
Placebo Comparator: Placebo Group receiving placebo |
Other: Placebo
Placebo
|
Outcome Measures
Primary Outcome Measures
- Symptom severity [24 weeks starting the day after enrollment]
Severity of symptoms
- Symptom duration [24 weeks starting the day after enrollment]
Length in days of symptoms
Secondary Outcome Measures
- Need for higher level of care/hospitalization [24 weeks starting the day after enrollment]
Comparison between groups of rates of hospitalization
Eligibility Criteria
Criteria
Inclusion Criteria:
- positive COVID test <= 7 days of enrollment
Exclusion Criteria:
-
pregnant
-
already hospitalized due to COVID
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Cambridge Health Alliance | Everett | Massachusetts | United States | 02149 |
Sponsors and Collaborators
- Cambridge Health Alliance
- The Thoracic Foundation
- Alturix